Alex Azar appears to be on a fast track to a relatively smooth confirmation as secretary of the US Department of Health and Human Services (HHS) – but the biopharma industry should expect drug pricing to be the subject of extra attention along the way.
The Senate Health, Education, Labor & Pensions Committee is set to kick off the confirmation process with a hearing Nov....






